48 completed, 13 unknown, 11 terminated, 10 recruiting. 47 Phase 2, 20 Phase 1, 11 Phase 3, 5 Not applicable, 2 Early Phase 1.
Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 3 | Recruiting | Washington University School of Medicine | 240 | 2026-11-02 | 2026-11-06 |
| CardioNETPOL National Registry of Carcinoid Heart Disease Observational Registry of Carcinoid Heart Disease - Carcinoid Heart Disease, Neuroendocrine Tumors | Not yet recruiting | National Institute of Cardiology, Warsaw, Poland | 120 | 2026-06-01 | 2026-03-04 | |
| Pharmaceutical Management in Targeted Radioligand Therapy Cancer, Thyroid Cancer | Recruiting | Hospices Civils de Lyon | 600 | 2026-01-09 | 2026-02-05 | |
| Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. RYZ401 - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 1 | Recruiting | RayzeBio, Inc. | 104 | 2025-12-03 | 2026-11-03 |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid | Phase 3 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 141 | 2025-11-19 | 2026-10-15 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| ALG-LungCancerRegistry (SAFRO2202) Observational Data Collection - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Recruiting | Société Algérienne de Formation et de Recherche en Oncologie | 3750 | 2025-06-01 | 2025-09-16 | |
| Life Following Excision of Neuroendocrine Tumors Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3 | Recruiting | Sunnybrook Health Sciences Centre | 246 | 2025-04-28 | 2025-05-20 | |
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors Everolimus 5 MG - Neuroendocrine Tumors, Progression | Phase 2 | Recruiting | AC Camargo Cancer Center | 100 | 2024-04-24 | 2024-06-25 |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) Lu-177-DOTATATE, Olaparib, Ga dotatate scanning - Gastroenteropancreatico Tumors, Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 56 | 2022-10-03 | 2026-10-16 |
| 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas | Unknown | European Institute of Oncology | 20 | 2022-05-12 | 2023-09-22 | |
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 36 | 2022-04-22 | 2026-03-19 |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease Transcatheter Tricuspid Valved Stent Graft - Tricuspid Regurgitation, Tricuspid Valve Disease | Not applicable | Active not recruiting | Queen Mary University of London | 15 | 2022-04-06 | 2026-11-19 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | RayzeBio, Inc. | 343 | 2022-03-24 | 2026-10-05 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors Cabozantinib, Nivolumab - Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 111 | 2022-01-21 | 2026-07-28 |
| Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors Telotristat Ethyl Oral Tablet - Neuroendocrine Tumors | Phase 2 | Withdrawn | University of Chicago | 2022-01-01 | 2021-12-17 | |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes PICO G2 4k - Cancer Pain, Visceral Pain | Not applicable | Recruiting | Cedars-Sinai Medical Center | 360 | 2021-10-05 | 2026-11-12 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors | Phase 4 | Completed | Advanced Accelerator Applications | 42 | 2021-01-25 | 2025-01-24 |
Showing 20 of 104. Sign in to see all of them.
Neuroendocrine Tumors (58) · Adenoma, Islet Cell (15) · Neoplasms (12) · Neoplasm Metastasis (11) · Serotonin Syndrome (11) · Neuroblastoma (9) · Pheochromocytoma (9) · Paraganglioma (8) · Carcinoma (7) · Carcinoma, Neuroendocrine (7) · Gastro-enteropancreatic neuroendocrine tumor (6) · Carcinoid Heart Disease (5) · Colorectal Neoplasms (5) · Pancreatic Neoplasms (5)
Neoplasms, Germ Cell and Embryonal (104) · Neoplasms, Nerve Tissue (104) · Neuroectodermal Tumors (104) · Neoplasms by Histologic Type (103) · Neoplasms, Glandular and Epithelial (103) · Adenocarcinoma (101) · Carcinoma (97) · Neoplasms (92) · Neuroendocrine Tumors (46) · Neoplasms by Site (40) · Endocrine System Diseases (33) · Endocrine Gland Neoplasms (32) · Digestive System Diseases (30) · Digestive System Neoplasms (30) · Pancreatic Diseases (27)
Everolimus (10) · Octreotide (7) · lanreotide (6) · gallium Ga 68 dotatate (5) · pasireotide (5) · Nivolumab (3) · Sunitinib (3) · cabozantinib (3) · lutetium Lu 177 dotatate (3) · Bevacizumab (2) · Capecitabine (2) · Erlotinib Hydrochloride (2) · Ga(III)-DOTATOC (2) · Temozolomide (2) · fluorodopa F 18 (2)
Novartis Pharmaceuticals (8) · Dana-Farber Cancer Institute (7) · British Columbia Cancer Agency (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Hospices Civils de Lyon (3) · Suez Canal University (3) · CHU de Reims (2) · Crinetics Pharmaceuticals Inc. (2) · Ipsen (2) · M.D. Anderson Cancer Center (2) · RayzeBio, Inc. (2) · Rutgers University (2) · SCRI Development Innovations, LLC (2) · Sue O'Dorisio (2) · University of California, San Francisco (2)
United States (65) · Canada (15) · France (12) · Italy (8) · Poland (8) · Germany (7) · Netherlands (7) · Spain (7) · Belgium (6) · Brazil (6) · United Kingdom (6) · Argentina (3) · Czechia (3) · Sweden (3) · China (2)
Francois Benard, MD (3) · Jonathan Strosberg, M.D. (3) · David Spigel, M.D. (2) · Jennifer Chan, MD, MPH (2) · Nancy Gardner, PhD (2) · Ye Yuan, MD (2) · Ajaykumar Morani (1) · Andreas Baumbach (1) · Andrei Iagaru (1) · Andrew Poklepovic, MD (1) · Angela Lamarca (1) · Aurel Perren, MD (1)
PMID 18391430, PMID 19097774, PMID 22119496, PMID 22736724, PMID 23187897, PMID 23475104, PMID 23516312, PMID 24800725, PMID 25376618, PMID 26769865, PMID 27214300, PMID 28153957, PMID 28444114, PMID 29149611, PMID 29181270, PMID 30158287, PMID 30506283, PMID 30943124, PMID 31682550, PMID 31754316, PMID 31980466, PMID 32359091, PMID 32392558, PMID 32919526, PMID 33382891, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36395401, PMID 36748723, PMID 37074571, PMID 37838323, PMID 38652200, PMID 38753757, PMID 39453770, PMID 39500789, PMID 39834129, PMID 39945192, PMID 39979665, PMID 40121391, PMID 41920388
2004 (1), 2005 (1), 2015 (1), 2019 (1), R01CA252211 (1)